<DOC>
	<DOCNO>NCT00517816</DOCNO>
	<brief_summary>This 8 arm study evaluate safety , tolerability , pharmacokinetics pharmacodynamics single ascend dos R1671 placebo patient mild , intermittent , asymptomatic asthma . Patients randomize receive placebo R1671 , start dose 0.0015mg , intravenous infusion ; dose escalate subsequent group patient satisfactory assessment data previous dose . The anticipated time study treatment &lt; 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Single Ascending Dose Study R1671 Patients With Mild Intermittent Asymptomatic Asthma .</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>adult patient , 1850 year age ; mild , intermittent , asymptomatic asthma ; history asthma &gt; =6 month ; nonsmoker . female childbearing potential , lactate ; history immunologically medicated disease ; systemic antineoplastic immunomodulatory treatment past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>